Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16315954 | 1.00 | MGLL (0.40) | MGLLALDH1A1ADORA1BRD4MEN1 | |
| SCHEMBL18751703 | 0.88 | MGLL (0.33) | MGLLBRD4KMT2A | |
| SCHEMBL17776064 | 0.88 | MGLL (0.33) | MGLLBRD4KMT2A | |
| SCHEMBL855021 | 0.88 | MGLL (0.33) | MGLLBRD4KMT2A | |
| SCHEMBL17776136 | 0.88 | MGLL (0.33) | MGLLBRD4KMT2A | |
| SCHEMBL594082 | 0.86 | BRD4 (0.46) | ALDH1A1BRD4GAA | |
| SCHEMBL594081 | 0.86 | BRD4 (0.46) | ALDH1A1BRD4GAA | |
| SCHEMBL26477235 | 0.85 | MGLL (0.36) | MGLLALDH1A1BRD4MEN1KMT2A | |
| SCHEMBL17553966 | 0.83 | PLG (0.47) | MGLL | |
| SCHEMBL18715716 | 0.83 | MGLL (0.32) | MGLLBRD4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002090-A1 | LIGAND-CYTOTOXIC DRUG CONJUGATE, PREPARATION METHOD THEREOF, AND USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002090-A1 | LIGAND-CYTOTOXIC DRUG CONJUGATE, PREPARATION METHOD THEREOF, AND USES THEREOF | LPXN, ADGRF1, LHCGR | MGLL 2381/4885ALDH1A1 3429/4885ADORA1 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.